Administration, Sales and R&D
We launched the first vaccine ever against cold water vibriosis - "saving" the Norwegian salmon industry and dramatically reduced the use of antibiotics
Introduction of the world's first oil based fish vaccine offering protection against furunculosis
Our State-of-the-art GMP production facility for fish vaccines opens in Overhalla, Norway
The first six component vaccine ever introduced in Norway. Includes protection against IPNV and winter ulcer.
ALPHA MAX® for bath treatment against salmon lice available in the Norwegian- and the Faroese market
Established office in Puerto Montt, Chile, later to become PHARMAQ AS Chile Ltda.
The first European fish vaccine ever approved by the Canadian authorities
Obtained approval in UK for the first virus vaccine for fish - protection against IPNV and furunculosis
PHARMAQ established 23 July by 'management buy out' of the Aquatic Animal Health business of Alpharma Inc.
Launch of our first generation SRS vaccine in Chile
MA approved for ALPHA JECT micro® 6 in Norway, the first six-component micro dose vaccine available
Sales license for ALPHA JECT® micro 3 in Chile, the first trivalent SRS micro dose vaccine available
PHARMAQ opened office in Vietnam, later to become PHARMAQ Ltd. VN
Acquisition of PHARMAQ by Orkla and Kverva
Extensive field trial of the first Pangasius vaccine started in Vietnam
PHARMAQ's first ISA vaccine received a provisional marketing authorisation from the Chilean authorities
PHARMAQ officially opened its PHARMAQ Turkey Ltd office in Izmir in May
PHARMAQ signed a long term agreement with Norwegian Institute of Public Health for lease of virus antigen production facilities in Norway
As the first fish vaccine commercially available in Vietnam, ALPHA JECT Panga 1 received a observation license
PHARMAQ Holding acquires Havbruksinstituttet AS
We make aquacultre progress!